A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the dietary supplement Siliphos, which comes from milk thistle, to determine whether it is safe and well-tolerated in adults who have non-alcoholic steatohepatitis (NASH). An additional aim of this study is to determine whether Siliphos may be beneficial in treatment of NASH as indicated by improvement in liver enzymes (ALT and AST). The study hypothesis is that Siliphos will be safe and well-tolerated in people with NASH and will result in a decrease in the liver enzymes ALT and AST.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Heather Patton; University of California, San Diego
• Collaborator: American College of Gastroenterology

Criteria

Inclusion Criteria:

• Liver biopsy within 12 months demonstrating NASH

• Abnormal ALT

Exclusion Criteria:

• Uncontrolled diabetes

• Hepatitis B, hepatitis C, or other chronic liver conditions

• Abnormal kidney function

• Excess alcohol consumption